Search PubMed⌕ Search

Biomedical subjects

C Salat

Publications and source records attributed to C Salat.

38 records · Page 3Linked to original sources

Fine structure of muscle and other components of the trunk of Sagitta setosa (Chaetognath).

The histology of the Chaetognath's trunk is largely based upon works of Hertwig (1880) and Burfield (1927) and is revised here essentially on ultrastructural basis, in a study on Sagitta setosa. The trunk is composed of a thick multilayered epidermis, without cuticle, and contains an abundant nervous system. It is separated from the underlying general musculature by a "basement membrane" which is not crossed by nerves fibres in the region of the ventral ganglion. We have been mainly interested in the muscular tissue. It has no close contact with the body cavity but is surrounded by a thin monolayer epithelium. The general musculature is composed of two types of muscles. The first one, forming the primary musculature, is divided by mesenteries and lateral fields into four quadrants. It contains groups of fibres (C then A) alternating with other groups of fibres (B). The second one, constituting the secondary musculature, is divided into four bands. Both types of fibres are readily identifiable by their myofibrils. The fibres of primary musculature, in close contact with their membrane level, have no basement lamina except at the myoepidermic junctions.

Animals↗

Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.

UNLABELLED: This pilot study analyzed the efficacy and toxicity of high-dose chemotherapy (HDCT), autologous stem-cell transplantation (ASCT) and subsequent immunotherapy with T-cell reinfusion and trifunctional antibodies (trAbs) in chemotherapy-sensitive patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: After leukapheresis and cryopreservation of T-cells, patients received 2 cycles of induction chemotherapy ET (epirubicin/paclitaxel) and 1 cycle of El (epirubicin/ifosfamide), followed by G-CSF and stem-cell harvest. After a final cycle of ET, responders (CR/PR) underwent HDCT (thiotepa 600 mg/m2/melphalan 140-180 mg/m2) and ASCT. Once reconstitution was achieved, T-cells were reinfused, followed by application of trifunctional antibodies with specificities anti-EpCAM X anti-CD3 and anti-Her2/neu X anti-CD3. RESULTS: Thirty-three patients were recruited into the study and 19, who had responded to initial chemotherapy, underwent HDCT and ASCT (4 CR, 15 PR, OR = 57.6%; 95% CI: 40-75%). Two early deaths were observed (1 toxic, 1 early progression). T-cell reinfusion and trAbs were given to 17 patients. TrAbs treatment resulted in intermittent fever, chills and elevated liver enzymes, which were seen in all patients. The median overall survival was 27.7 months (range: 5.9-82.6+). Patients who received 3 trAbs doses showed a trend towards an improved overall survival (47.2 vs. 22.4 months, p = 0.08 log rank). CONCLUSION: This pilot study has shown the feasibility of combining HDCT with immunotherapy in MBC. Further investigation of this approach is indicated.

Adult↗